NEW YORK (GenomeWeb News) — Navigenics, a Bay Area company focused on using whole-genome scanning to identify an individuals’ genetic risks for certain diseases, today said it has made its official debut as a company.
 
The firm said it has also secured a Series B round of venture capital financing for an undisclosed amount, bringing its total funding to $25 million to date.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.